Case Report And Literature Review Of Vemurafenib For Treating BRAF^V600E Mutant Metastatic Colorectal Cancer

Vemurafenib is a serine/threonine protein kinase inhibitor with relatively low molecular weight and can be used orally.On August 17,2011.The F ood and Drug Administration?FDA?has approved the treatment of BRAF^V600E mutant melanoma in adults who cannot be surgically removed or metastasized.Colorectal Cancer?CRC?is one of the leading causes of cancer-related morbidity and mortality.In the advanced stage of Colorectal Cancer,molecular targeted individualized therapy has entered clinical practice.In colorectal cancer,the mutation rate of BRAF is about 9.6%,80%of which is caused by the mutation of thymine?T?at the 1799 site of exon 15 into adenine?A?,so that the 600th amino acid of its encoding product is transformed from valine?V?to glutamic acid?E?.Colorectal cancer patients with BRAF V6000E mutation have a poor prognosis.BRAF inhibitors is the latest method of targeted therapy for colorectal cancer with BRAF^V600E mutation.In this case report,we shared our experience with the treatment of BRAF^V600E mutated left colorectal adenocarcinoma with the BRAF inhibitors vemurafenib and reviewed the relevant literature.We reported a 53-year-old male patient with BRAF^V600E mutation of left colorectal adenocarcinoma.The patient who failed with second-line therapy received vemurafenib and he benefited 8 months progressive free survival?PFS?and 11 months overall survival?OS?.BRAF^V600E mutated colorectal adenocarcinoma patients had a expected overall survival of 4.7 months.In conclusion,the emerence of BRAF inhibitors provides a new strategy for the treatment of colorectal cancer patients with BRAF^V600E mutation.